Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SHC Stock Forecast 2026-2027
$15.62
Current Price
$4.45B
Market Cap
Buy 9
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SHC Price Targets
+53.6%
To High Target of $24.00
+28.0%
To Median Target of $20.00
+2.4%
To Low Target of $16.00
SHC Price Momentum
+0.5%
1 Week Change
-1.0%
1 Month Change
+27.0%
1 Year Change
-11.5%
Year-to-Date Change
-21.3%
From 52W High of $19.85
+44.7%
From 52W Low of $10.80
📊 TOP ANALYST CALLS
Did SHC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sotera Health is one of their latest high-conviction picks.
Latest SHC Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, SHC has a bullish consensus with a median price target of $20.00 (ranging from $16.00 to $24.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $15.62, the median forecast implies a 28.0% upside. This outlook is supported by 9 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sean Dodge at RBC Capital, projecting a 53.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SHC Analyst Ratings
9
Buy
2
Hold
0
Sell
SHC Price Target Range
Low
$16.00
Average
$20.00
High
$24.00
Current: $15.62
Latest SHC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SHC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 5, 2026 | Goldman Sachs | Evie Koslosky | Buy | Initiates | $20.00 |
| May 6, 2026 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $22.00 |
| Apr 14, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 24, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Jan 9, 2026 | RBC Capital | Sean Dodge | Outperform | Reinstates | $24.00 |
| Jan 9, 2026 | Piper Sandler | Overweight | Upgrade | $N/A | |
| Dec 18, 2025 | William Blair | Outperform | Initiates | $N/A | |
| Nov 13, 2025 | BMO Capital | Outperform | Initiates | $N/A | |
| Nov 5, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Nov 5, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 5, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Oct 2, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Jun 24, 2025 | Barclays | Overweight | Maintains | $N/A | |
| May 5, 2025 | Goldman Sachs | Buy | Upgrade | $N/A | |
| Apr 23, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Apr 10, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Feb 28, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Feb 18, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Nov 21, 2024 | RBC Capital | Outperform | Reiterates | $N/A | |
| Nov 6, 2024 | Citigroup | Buy | Maintains | $N/A |
Sotera Health Company (SHC) Competitors
The following stocks are similar to Sotera Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sotera Health Company (SHC) Financial Data
Sotera Health Company has a market capitalization of $4.45B with a P/E ratio of 38.1x. The company generates $1.19B in trailing twelve-month revenue with a 9.9% profit margin.
Revenue growth is +10.0% quarter-over-quarter, while maintaining an operating margin of +31.3% and return on equity of +22.7%.
Valuation Metrics
Market Cap
$4.45B
Enterprise Value
$6.41B
P/E Ratio
38.1x
PEG Ratio
-0.1x
Price/Sales
3.7x
Growth & Margins
Revenue Growth (YoY)
+10.0%
Gross Margin
+52.5%
Operating Margin
+31.3%
Net Margin
+9.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
2.8x
Debt/Equity
364.7x
ROE
+22.7%
ROA
+8.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sotera Health Company (SHC) Business Model
About Sotera Health Company
What They Do
Provides critical health and sterilization services.
Business Model
The company operates through three business units: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers sterilization solutions using advanced technologies, while Nordion supplies Cobalt-60 for radiation sterilization. Nelson Labs provides testing and consultancy services to help organizations meet regulatory standards, generating revenue through service contracts and product sales.
Additional Information
Sotera Health plays a vital role in ensuring safety across multiple industries, including medical devices, pharmaceuticals, and food safety. Its integrated solutions are essential for regulatory compliance and public health, and the company has a significant international presence that underscores its reliability in delivering safety standards.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
3,000
CEO
Mr. Michael B. Petras Jr.
Country
United States
IPO Year
2020
Website
soterahealth.comSotera Health Company (SHC) Latest News & Analysis
Latest News
Sotera Health Company (SHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript
5 days ago
Quick Summary
Sotera Health Company (SHC) recently presented at the Jefferies Global Healthcare Conference, discussing its business developments and future outlook.
Why It Matters
Sotera Health's presentation at a major healthcare conference signals potential growth opportunities and insights into its strategic direction, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Sotera Health Company (SHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
19 days ago
Quick Summary
Sotera Health Company (SHC) presented at the RBC Capital Markets Global Healthcare Conference 2026. Further details on the presentation were not provided in the excerpt.
Why It Matters
Sotera Health's presentation at a major conference signals potential insights into its strategy and performance, affecting investor perceptions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Valvoline was a top performer for Broyhill, with strong unit growth and pricing. Honeywell plans to spin off its aerospace unit by June, enhancing its automation business value. IQVIA remains crucial for pharma's FDA processes.
Why It Matters
Valvoline's strong performance signals solid fundamentals, while Honeywell's spin-off may unlock value. IQVIA's essential role in pharma highlights stability amid AI uncertainties, impacting investment strategies.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Sotera Health Company announced a secondary offering of 31,838,253 shares of common stock, solely from affiliates of Warburg Pincus and GTCR as selling stockholders.
Why It Matters
The secondary offering of over 31 million shares may dilute existing shareholders' equity and affect the stock price. It indicates potential changes in ownership dynamics and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sotera Health Company (SHC) held its Q1 2026 earnings call, providing insights into financial performance and strategic developments. Further details are available in the transcript.
Why It Matters
Sotera Health's Q1 2026 earnings provide insights into financial performance and growth, impacting stock valuation and investor confidence in the company's future prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sotera Health's Q1 2026 net revenues rose 10.0%, with net income at $27M ($0.09/share) vs. a loss last year. Adjusted EBITDA increased 10.5%. Full-year growth outlook reaffirmed at 5.0%-6.5%.
Why It Matters
Sotera Health's revenue and net income growth signals financial health, while reaffirming its outlook suggests stability. CEO transition may impact future strategy, affecting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SHC Stock
What is Sotera Health Company's (SHC) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Sotera Health Company (SHC) has a median price target of $20.00. The highest price target is $24.00 and the lowest is $16.00.
Is SHC stock a good investment in 2026?
According to current analyst ratings, SHC has 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SHC stock?
Wall Street analysts predict SHC stock could reach $20.00 in the next 12 months. This represents a 28.0% increase from the current price of $15.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sotera Health Company's business model?
The company operates through three business units: Sterigenics, Nordion, and Nelson Labs. Sterigenics offers sterilization solutions using advanced technologies, while Nordion supplies Cobalt-60 for radiation sterilization. Nelson Labs provides testing and consultancy services to help organizations meet regulatory standards, generating revenue through service contracts and product sales.
What is the highest forecasted price for SHC Sotera Health Company?
The highest price target for SHC is $24.00 from Sean Dodge at RBC Capital, which represents a 53.6% increase from the current price of $15.62.
What is the lowest forecasted price for SHC Sotera Health Company?
The lowest price target for SHC is $16.00 from at , which represents a 2.4% increase from the current price of $15.62.
What is the overall SHC consensus from analysts for Sotera Health Company?
The overall analyst consensus for SHC is bullish. Out of 4 Wall Street analysts, 9 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are SHC stock price projections?
Stock price projections, including those for Sotera Health Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 3:57 PM UTC